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ABSTRACT 
Thyroid hormone serves as an indispensable component for the optimum functioning of various biological systems. They curb body’s metabolism, 
regulates the estrogen level, regulates bone turnover, essential for skeletal development and mineralization. Within the scope of knowledge, it is 
intimately familiar that thyroid disorders have widespread systemic manifestations, among which in hypothyroidism, even though elevated TSH 
(thyroid-stimulating hormone) may reduce estrogen level which in turn stimulates osteoclasts and thus cause osteoporosis, while hyperthyroidism 
accelerates bone turnover. Hypothyroidism does not directly interfere with the skeletal integrity, but treatment with levothyroxine for the 
suppression of TSH to bring the hypothyroid patient to euthyroid state for a long haul; lead to simultaneous reduction in bone mass and in (bone 
mineral density) BMD. 
After the initial relevation of the correlation between thyroid disorders and osteoporosis in numerous studies have emphasized that both hypo and 
hyperthyroidism either directly or indirectly affects the bone mineral density or leads to the progression of osteoporosis. 
Therefore the present study is aimed and so designed to review all the possible associations between them and the impact of thyroid disorders on 
estrogen level and bone mineral density.  
The main findings of this review indicate that both excesses as well as deficiency of thyroid hormone can be potentially deleterious for bone tissue.  
Keywords: Bone cells, Bone mass, Calcium, Chondrocytes, Estrogen, Interleukins, Levothyroxine 




Osteoporosis is one of the most plebeian progressive skeletal 
diseases described by the quirky disorientation of bone tissue and 
bone mass. It can affect a person of any age, gender and groups, but 
in older people, there is a steep increase in the incidence of fracture 
[1]. The struts that make a mesh-like structure within bones become 
thin, causing the bone to become fragile, which lead to break them 
easily and increases the incidence of fracture [2]. 
Breaking of bones and fragile bone has the same meaning and 
sometimes we can use both the terms interchangeably. In 
osteoporosis, the susceptibility to fracture gets increased which is 
characterized by abnormal architectural arrangement of bone tissue 
[3]. In a person with osteoporosis a minor bump or fall is sufficed to 
break the bone [4]. The most common parts that get affected by 
osteoporosis are the spine, hip, wrists (forearm) and shoulder [5]. 
There are two main hypotheses which we can relate to the 
development of osteoporosis. The first one is–ineluctable 
breakdown of bones due to changes in bone matrix which leads to 
wasting of bones and other tissue. It is generally associated with age. 
The second one is the nutritional hypothesis which generally 
accomplishes two main nutrients (calcium and protein) [5]. A report 
was also released by the United State government in 2004 with a 
recommendation for physician that, it is mandatory to adopt a 
pyramidal approach for osteoporosis. The third level includes 
treatment either with anabolic medications or antiresorptive 
medications. The second level includes the management and 
secondary cause of osteoporosis and the baseline include nutrients 
such as calcium and Vitamin D as well as physical therapy such as 
fall prevention [6]. 
If osteoporosis remain untreated for a long haul it gives rise to 
unnecessary extreme pain, altered body posture, disability in 
moving, climbing stairs and increased mortality [7]. Spinal fracture 
sometimes called vertebral fracture, which may lead to quirky 
curvature of the spine and loss of height [8].  
With the wide range of condition Receptor activator of nuclear 
factor κ β ligand (RANK-L) is responsible for mediating the 
osteoclast-mediated bone resorption [9]. RANK-L (317 amino acid 
peptide) is the bone-specific gene and have a major role in 
stimulating, differentiation and inhibition of osteoclasts apoptosis 
[10]. For physiological reclamation of osteoclast some kind of cells 
and cytokines are responsible. In the bony surface the monocyte 
osteoclast precursors, activate, proliferate and fuse to form 
multinucleated osteoclasts and expresses a "receptor on their 
surface, for the activation of nuclear factor k-beta (RANK). In the 
presence of trophic factor M-CSF (Macrophage colony-stimulating 
factor) RANK-Ligand binds to this receptor. Binding of RANK-L to 
RANK, transformed osteoclast precursor to mature osteoclast and 
the process of bone resorption will take place and a bone resorption 
pit is formed. Osteoprotegerin (another protein) prevents the 
binding of RANK-L to RANK thus prevents bone resorption [11]. 
German pathologist Pomner originated the term osteoporosis by 
using three bone disorders. Osteomalacia (softening of bones) is a 
condition where a large number of unqualified bone tissue. It is due 
to the deficiency of Vitamin D and calcium. Osteoporosis (weak and 
brittle bones) is a condition where a large number of bone tissue are 
calcified and osteitis fibrosa, is a complication of 
hyperparathyroidism, where bone is eroded by osteoclasts and 
replaced with fibrous tissue [12]. The first case of osteoporosis was 
reported by Von Recklinghausen in 1891 in a young lady, who died 
due to hyperthyroidism with a feature of “worm-eaten appearance 
of long-bones”, while in 1920 another researcher Plummer reported 
the same case with similar descriptions. Their finding indicates that 
thyroid disorder is a risk factor for osteoporosis and routine 
monitoring of thyroid hormones is mandatory [13]. Osteoporosis 
characterized by excessive bone loss, too little bone formation, or a 
combination of both [14]. 
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Fig. 1: Schematic diagram for bone formation and bone resorption [11] 
 
Classification 
In order to achieve the information on facts (diabetes, endocrine 
disorder (a thyroid disorder), that affect bone metabolism, 
osteoporosis can be divided into two types. 
Primary  
The exact cause is unknown but can be associated with aging. 
Conditions such as menopause may accelerate that.  
Despite this Primary osteoporosis can be further divided into two 
types. Involutional osteoporosis, type-1 (due to deficiency of 
estrogen and also known as postmenopausal osteoporosis) and 
involutional osteoporosis, type-II (loss of bone mass due to aging of 
trabecular and cortical bones thus also called as senile/doddering 
osteoporosis).  
Secondary  
Is caused by something else, factors such as genetic disease (cystic 
fibrosis, Marfan syndrome and Gaucher’s disease), endocrine 
disorders (Cushing’s syndrome, hyperparathyroidism, 
thyrotoxicosis, hyperprolactinemia and diabetes mellitus), 
Gastrointestinal disorder (Celiac disease and Malabsorption) and 
medications such as prednisone are responsible for the 
development of secondary osteoporosis [15, 16].  
Idiopathic Juvenile Osteoporosis (IJO) with unknown causes and 
occurs just before the onset of puberty, but the lucky one experience 
complete recovery of bone. Average age at onset is seven years while 
the range is 1 to 13 y [14].  
Epidemiology 
A large number of populations are suffering from osteoporosis, this 
attracts the attention of orthopedic surgeons and physician in North 
America and Europe and this comes to lightning as a very common 
disease. Osteoporosis is an alarming issue in some countries such as 
India. Although it is a sun-rich country, still deficiency of vitamin D is 
a very common issue for the people of any age but women’s are 
more susceptible to osteoporosis. It has been estimated that till 
2015 about 230 million Indians have been diagnosed with 
osteoporosis among which 20% are women [17]. The Third National 
Health and Nutrition Examination Survey revealed that in the U. S. 
up to 13 million men having age 50 or more than 50, have low bone 
mineral density (BMD) and from these up to 02 million people 
having osteoporosis [18]. For British white women with age of 50 y 
the incidence of osteoporotic fracture of hip, spine and radius is 
14%, 11% and 13%, respectively but the incidences are high for 
North American women and i.e. 17.5%, 15.55% and 16% 
respectively. In whites (European) hip fractures are more common 
among all other kinds of fracture [19].  
Risk factors 
Insights are drawn from the scholarly literature the potential risk 
factors that can predispose to osteoporosis are shown in the table 
[15, 19]. 
  
Table 1: Risk factor associated with the progression of osteoporosis 
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Diabetes mellitus type 1.  
Untreated 
hypogonadism.  
Low body weight. 
Malignancy. COPD.  
Hyperparathyroidism 
Stroke, rheumatoid 
arthritis, sex hormone 
deficiency.  
Cytotoxic agents, 






Osteoporosis is considered as a silent disease [20] because people 
are less aware of it and do not experience any symptoms prior to 
the fracture. The pain from which a patient is going through 
consider it as a part of its normal routine resulting the patient 
remains untreated and undiagnosed from osteoporosis. Gender is 
the most dominant risk factor for osteoporosis. The bones of 
postmenopausal women are more susceptible to fracture than 
premenopausal due to diminished levels of estrogen (by 
hypothyroidism), which reduces absorption of calcium. For 
maintaining the estrogen level kept in line plant phytoestrogens 
are considered to be best. In the true sense they are polyphenolic 
in nature and due to large content of antioxidant they also possess 
anti-osteoporotic activity [21].  
Another key point to remember is that, in order to prevent the 
chances of osteoporosis, for the correct and normal functioning as 
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well as for the concordant development of bone there are some 
factors that has to be focused, such as genetic conditions, metabolic, 
hormonal homeostasis, mechanical load, and balanced diet. 
Fractures that are caused by falling from the height are not 
considered as the osteoporosis fracture because people presenting 
such type of fracture have normal bone mineral density (BMD) as 
well as the normal architectural arrangement of bone tissue, while 
the reduced BMD (osteopenia) [22], bone fragility and abnormal 
architectural arrangement are the representatives of osteoporosis 
fracture.  
Pathogenesis and assessment of osteoporosis  
The pathogenesis of osteoporosis accrued by aging, lack of estrogen 
(menopause), thyroid disorders and excessive release of cytokines 
(play a major role in the regulation of bone resorption) due to 
chronic inflammatory disease and increased oxidative stress [10]. 
  
 
Fig. 2: Pathogenesis and assessment of osteoporosis [8] 
 
Rossini M et al. Evaluated the adverse reactions and safety issues of 
drugs used in the management of osteoporosis. Their findings 
suggest that a large number of licensed drugs are used in the 
treatment of osteoporosis over the last 2 decades, some of them are 
listed below, such as-Calcium, Vitamin D, Bisphosphonates, selective 
estrogen receptor modulators, denosumab and teriparatide having 
long term safety, while the license for treating osteoporosis with 
calcitonin was recently withdrawn [23].  
Osteoporosis is somehow, somewhere linked with endocrine 
disorders (a thyroid disorder), so the central issue addressed here is 
to establish the link between thyroid disorder and Osteoporosis.  
How thyroid hormone affects the skeletal integrity and what are 
their effects on human physiology can be assessed by examining the 
adverse consequences of both (hypo and hyperthyroidism). Among 
thyroid disorder, hyperthyroidism independently accountable for 
the prolonged activation of osteoclast which leads to the induction 
of bone loss in adults, while hypothyroidism is not a potent risk 
factor for osteoporosis [24]. Overproduction of thyroid hormone 
from butterfly-shaped endocrine gland can be responsible for 
deterioration of bone by misbalancing the rate of formation of a new 
bone and bone resorption collectively known as bone turnover, that 
generally takes 200+days, but in case of hyperthyroidism this cycle 
takes only 130-140 d for the completion; thus bone turnover hasten 
by hyperthyroidism and an increase in bone turnover is a familiar 
risk factor for osteoporosis fracture [25]. The patient has any kind of 
thyroid problems, especially overt hyperthyroidism generally 
suffers from proximal limb muscle weakness (proximal myopathy), 
which upon treatment get resolved [26]. 
Influence of thyroid hormone on growth and development of 
bone: molecular mechanism 
The actions of thyroid hormone on bone are mediated by thyroid 
hormone receptors (TRs) such as THR alpha 1, alpha 2 and THR 
beta1, beta 2. And these THRs are encoded by THRA and THRB 
genes. During bone growth tri-iodothyronine stimulates bone mass, 
thus exerts its anabolic effect, but has a catabolic effect on adult 
bone and stimulates bone turnover. Not only throcytes but the 
majority of human cells and tissue express thyroid hormone 
receptors on their surface. Deficiency of thyroid hormone in children 
leads to delayed bone age, arrest in bone growth followed by 
epiphyseal dysgenesis and retardation in skeletal development [27]. 
(A) In hypothyroid state the activity of Iodothyronine Deiodinase 2 
(DIO2) is considered as maximum while the activity of 
Iodothyronine Deiodinase 3 (DIO3) is minimum due to this factor 
the thyroid hormone receptor called thyroid hormone receptor 
alpha 1 (TR α1) binds only to corepressor, thus remains unliganded 
and inhibit T3 target gene transcription. (B), in the euthyroid state, 
the optimized intracellular activity/availability of T3 is mediated by 
D2 and D3, by which the displacement of co-repressor takes place. 
(C), despite this In case of thyrotoxicosis (a reverse form of 
hypothyroidism), the activity of D3 is maximized while the activity 
of the D2 is minimized, thus T3 gene transcription enhanced due to 
prolonged/increased activation of TR α1 [28]. 
Osteoblasts, osteoclasts, osteocytes and chondrocytes are the major 
component required for the growth and maintenance of bone cells, 
among which osteoblasts and chondrocytes are directly related to 
thyroid hormones and are responsive to thyroid hormones. The 
activity of osteoclast is also sensitive to changes in thyroid status 
[29]. An established cause of secondary osteoporosis is considered 
as thyrotoxicosis while the change in thyroid status due to abnormal 
thyroid hormone signaling has recently been identified as a novel 
risk factor for osteoarthritis [30]. The process of proliferation and 
differentiation of bone cells, including chondrocytes, osteoblasts and 
osteoclasts is regulated by thyroid hormone [31]. 
Both osteoblast (bone-forming cells) and osteoclast (absorb bone 
during growth and healing) get stimulated in response to thyroid 
hormone. But the action of thyroid hormone in osteoclast is more 
prominent, resulting grievous reduction in bone mass. In order to 
achieve a euthyroid state with the suppressive dose of levothyroxine 
is responsible for decreasing bone mass and bone mineral density, 
which are associated with increased fracture risk [32]. 
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Fig. 3: Influence of thyroid hormone on bone cells [28] 
 
Douglas C, et al. in his prospective study evaluated that in the older 
women low level of thyrotropin is not associated with bone loss. He 
noticed that in postmenopausal women, having age above 65 y, low 
level of thyroid hormone as well as TSH are not linked to bone loss 
[33]. Another study has been carried out by Susan L, et al. for the 
evaluation of the outcomes of skeletal function from the treatment of 
levothyroxine for a long haul in pre as well as postmenopausal 
women. They provide a positive data along with supportive evidence 
that indicates treatment with L-thyroxine for a longer duration 
might bring changes in skeletal integrity and associated with a 
depreciated bone mineral density of the hip and spine [34]. 
A study, which was conducted on a large number of populations 
indicates that thyroid function abnormality directly or indirectly 
might be associated with increased fracture risk and reduced bone 
mineral density that can affect both sexes [35]. Greet Roef et al. have 
evaluated that physiological range of thyroid hormones affects the 
peak bone mass and bone density in a healthy man. They noticed 
that In healthy men at the age of peak bone mass, between-subject 
variation in thyroid hormone concentrations affects bone density, 
with higher levels of FT3, TT3, TT4, and TBG being associated with 
less favorable bone density and content [36].  
Influence of hyperthyroidism or subclinical hyperthyroidism 
on skeletal health 
Hyperthyroidism is a condition indicating the excess circulating 
level of thyroid hormone combinelly known as T3 and T4. In 
childhood, excess thyroid hormone cause premature accretion of 
growth plates, cranial sutures which ultimately lead to 
craniosynostosis and short stature. While a reduced bone mineral 
density and increased bone turnover is observed in hyperthyroid 
adults [37]. Despite this improvement in bone mineral density is 
observed on treatment of hyperthyroidism to euthyroid state [38]. 
Studies reveal that hyperthyroidism has a prejudiced effect on bone 
mineral density leads to reduced bone mass and increases the risk of 
fracture [39].  
In the patient of hyperthyroidism the urine as well as fecal excretion 
of calcium get increases by three to four times due to alterations in 
the metabolism of calcium and phosphorus made by a hyperactive 
thyroid gland (hyperthyroidism) resulting in a condition termed as 
hypercalcemia. In contrast, to control subjects, the mean serum 
calcium level of hyperthyroid patients are 2-3 times higher and this 
is due to abnormal efflux of calcium from the kidneys, skeleton and 
gastrointestinal tract [40]. In pre osteoblastic cells, it has been 
observed that tri-iodothyronine increases the expression of mRNA 
of RANKL (key molecule responsible for the activation of osteoclast 
and osteoclastogenesis synthesized from osteoblasts) [41, 42].  
Subclinical hyperthyroidism  
Subclinical hyperthyroidism is a condition characterized by low or 
undetectable serum levels of thyroid-stimulating hormone (TSH), 
while the levels of thyroid hormones (T3 and T4) remain unaffected. 
Low or undetectable TSH levels are associated with increased bone 
turnover markers, especially in postmenopausal women [43]. In the 
body of literature, it has been indicated that subclinical 
hypothyroidism is associated with reduced bone mineral density 
and increases the risk for a bone of getting fractured especially in 
women [41]. 
Mudde AH, et al. has evaluated the peripheral bone density in 
women with untreated multinodular goiter, he noted that subclinical 
hyperthyroidism with multinodular goiter is associated with 
decreased BMD in pre as well as postmenopausal women. It has also 
been concluded from this study that bone mineral density of the 
forearm is decreased in women with subclinical hyperthyroidism 
[44]. Folds, J et al. have investigated the bone mineral density in 
patients with endogenous subclinical hyperthyroidism. Dual X-Ray 
absorptiometry was used for the measurement of the bone mineral 
density of the lumbar spine, femoral and Neck. This study concluded 
that in postmenopausal women with subclinical hyperthyroidism, 
there is a decrease in bone mineral density of spine, femoral neck 
and forearm, while no significant effect is seen in premenopausal 
women with subclinical hyperthyroidism [45]. 
MC Dermott et al. have observed a longitudinal assessment of bone 
loss in women with levothyroxine suppressed benign thyroid 
disease and thyroid cancer. In contrast to controls, the rate of bone 
loss was greater in levothyroxine suppressed patients. In aggregate 
insights drawn from this article suggests the association between 
bone loss (cortical region) and levothyroxine suppression that 
indicates a reduced bone mineral density [46]. Campus-pastor MM, 
et al. noted that there is a significant decrease in bone mineral 
density in the lumbar spine, femoral neck and ward triangle in 
postmenopausal women. Their findings suggest that thyroid 
hormone exerts their deleterious effect on bone mineral density, 
which may turn into osteoporosis [47]. In 2010, Lee J, et al. and 
other-investigated the effect of subclinical hyperthyroidism on 
skeletal function and noted that the incidence of hip fracture 
increases in older patients with subclinical hyperthyroid function. 
They also concluded that the BMD of the femoral neck, but not of 
lumbar spine has been decreased in women with subclinical 
hyperthyroidism [48]. In 2015, Blum MR, et al. and others evaluated 
that subclinical hyperthyroidism was associated with an increased 
risk of hip and other fractures [49]. 
In order to achieve some other sort of information Vadiveloo T, et al. 
noted that patients with endogenous subclinical hyperthyroidism 
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are associated with increased fracture risk along with a hazard ratio 
of 1.25-1.26 and are associated with osteoporosis, which get 
abolished after the achievement of overt hyperthyroidism or thyroid 
state [50]. Another researcher Tauchmanova L, et al. in his cross-
sectional study indicated that there is a significant decrease in bone 
mass mainly cortical region in women with endogenous subclinical 
hyperthyroidism while a significant increase in the rate of bone 
turnover markers [51]. The controversial data obtained from the 
papers published in the JCEM indicates that there is no any 
relationship has been associated with subclinical thyroid function 
and bone mineral density [52, 53].  
Influence of hypothyroidism or subclinical hypothyroidism on 
skeletal health 
For perpetuation as well as maintenance of bone mass and growth of 
bone tissue thyroid hormone serves as an important factor. If 
hypothyroidism remains untreated for a longer period of duration 
the growth of bone tissue goes into a negative direction i.e. growth 
arrest. There is a decrement in the formation of bone cells, leads to 
growth retardation, short stature and the process of endochondral 
ossification get disturbed [54, 55].  
Generally, hypothyroidism leads to a decrease in metabolism and 
also slows down other biological processes. Kosińska A et al. 
evaluated the effect of thyroxine treatment (substitute or 
suppressive doses) on bone turnover markers. They noticed that in 
pre and postmenopausal women the osteogenic and osteoclastic 
activity increases in treatment with thyroxine. Thyroxine when used 
as a suppressive dose it is solely accountable for the stimulation of 
bone turnover markers in comparison to substitute dose. There is an 
elevation in serum concentrations of vitamin D, parathyroid 
hormone while serum level of osteocalcin and alkaline phosphatase 
and the amount of urinary calcium i. e calciuria or calciuria has been 
decreased [56].  
In the year of 2000 researcher Vestergaard P, et al. evaluated the 
risk of fractures in patients having primary idiopathic 
hypothyroidism. They noticed that there is the development of 
temporary fracture of short duration of 2 y and which was limited to 
forearm only, but the overall risk for a bone of being fracture is 
increased twice in comparison to control individuals [57]. Despite 
this, in order to achieve some extra information Vestergaard P, et al. 
further evaluate the influence of treatment with antithyroid drugs 
and levothyroxine on fracture risk and the effect of hypo and 
hyperthyroidism. After diagnosis of hyperthyroidism the chances of 
fracture increased within the first 5 y, while after diagnosis of 
hypothyroidism the chances still increase within first 10 y. There is a 
significant increase in the reduction of fracture risk after treatment 
with antithyroid medications [58].  
Ross DS noted that there is no significant reduction in bone mineral 
density of forearm and spine in postmenopausal women with 
subclinical hypothyroidism [59].  
Supporting attestation  
Effect of thyroid disorder on estrogen depletion 
Thyroid autoimmunity is the most prominent cause of thyroid 
dysfunction, especially in the reproductive age women [60]. It is 
intimately familiar that thyroid hormone exerts their action by 
acting on thyroid hormone receptors that are present in the human 
ovarian surface epithelium [61]. Hypothyroidism adversely 
manipulates the female reproductive physiology in several ways, it 
disturbs estrogen metabolism, increases prolactin levels above 25 
ng/ml, which in turn inhibits the pulsatile secretion of 
gonadotropins [62]. In hypothyroidism, there is an increase in the 
level of TRH, followed by increased secretion of TSH [63]. The 
follicle number and fertility has been decreased due to down 
regulation of thyroid hormone receptors (TRs) [64]. 
Hypothyroidism affects the female reproductive hormones, reduces 
the amount of sex hormone-binding globulin and androgen. It 
induces fluctuations in estrogen levels in females, which may lead to 
decreased amount of estrogen and testosterone, but the free level of 
these hormones gets increased [65]. Fluctuation in the level of 
estrogen leads to ovarian dysfunction; hence maturation of oocytes 
does not take place while other abnormalities are associated with 
depletion in the level of estrogen which directly or indirectly linked 
with the development of osteoporosis.  
The metabolic clearance of estrone and androstenedione may get 
reduced and aromatization of peripheral estrogen may get increased 
[66, 67]. The receptor-mediated action of estrogen gets reduced due 
to inhibition in binding activity of estrogen with its receptor by 
hypothyroidism [68]. A variety of dysfunctions which are adversely 
manipulated by hypothyroidism are menstrual irregularities, 




Fig. 4: Effect of hypothyroidism on estrogen level [65-67] 
 
Effect of estrogen on skeletal integrity: molecular mechanism 
The effects of estrogen on the bone matrix are complex, but it seems 
that estrogen plays a pivotal role in skeletal health. For the growth 
and maturation of bone estrogen is considered to be an important 
factor and in adults, it also helps in the regulation of bone turnover 
[70]. Estrogen exerts a protective effect on bone as estrogen 
receptors are found on osteoblasts and osteoclasts; thus the tissue of 
bone is responsive to estrogen [71].  
In postmenopausal women there is a rapid bone loss, accelerates 
continuously after menopause. In postmenopausal women, it seems 
that bone resorption exceeds than its formation due to the declining 
level of estrogen hence women of postmenopausal age are more 
susceptible to osteoporosis [72]. Estrogen shield, bone loss by 
suppression of inflammatory cytokines such as interleukin (IL-1, IL-
6), slowing bone decay, and hence reducing fracture risk [73]. 
Teresa S, et al. evaluated the bone protective effects of estrogen and 
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the association between differential IL-1 receptor regulations in 
human osteoclast–like cells and identified that in bone marrow 
stromal cells and in primary human osteoblasts estrogen did not 
alter the level of IL-1receptor levels but control them. While during 
deficiency of estrogen level, especially in older women leads to 
osteoclast mediated bone loss [74]. 
  
 
Fig. 5: Effect of estrogen on bone remodelling [11] 
 
The bone loss, which leads to the deficiency of estrogen is represented 
and elaborates in this representational diagram. Estrogen is 
responsible for the apoptosis of cytokines and some hormones. On the 
other hand the interleukin-7 (IL-7) level increases when the level of 
estrogen decrease as well as decreasing the production of 
transforming growth factor-beta (TGF-β) and increase the production 
of insulin-like growth factor-1 (IGF-1). By this activation of T cell 
occurs which leads to the liberation of type II interferon (IFN-γ) which 
raises the antigen presentation which is necessary for triggering the T 
cell immune response. Low levels of estrogen also affects the 
antioxidant pathway by increasing the level of ROS [11].  
Stimulation of inflammatory cytokines apoptosis and a reduction in 
osteoclastogenesis begins with the initiation of estrogen 
replacement therapy (ERT) and bone loss minimized to an extent 
after long term use of ERT [75].  
The process of Bone resorption gets inhibited by estrogen followed 
by the synthesis of IL-1, IL-6, TNF-α and PGE2. These are the 
stimulator of osteoclast synthesis. Estrogen also exerts an 
antagonistic action on IL-6 receptors, so transgenic mice lacking the 
IL-6 receptor do not develop osteoporosis [76]. The pro-
inflammatory mediators IL-1 are involved in the pathogenesis of 
various diseases and increases the rate at which bone is lost. It also 
stimulates the progression of osteoporosis [77], followed by 
rheumatoid arthritis [78]. Estrogen, androgens, vitamin D and other 
circulating hormones, including parathyroid hormone regulates 
bone remodelling cycle.  
Another mechanism indicates that osteoclast apoptosis is also 
regulated by estrogen. In the absence of estrogen the life span of 
osteoclast increases due to reduced apoptosis, which prolongs the 
resorption phase of the remodelling cycle [79]. 
  
 
Fig. 6: Effect of estrogen level depletion on bone health 
 
In postmenopausal women, estrogen replacement therapy improves 
Bone Mineral Density (BMD). Over 35 y ago, Lindsay and colleagues 
demonstrate that in oophorectomized women, the bone loss gets 
prevented by estrogen while withdrawal of estrogen exerts an 
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opposite effect. Despite this it has been also established that like 
estrogen the other dominant sex hormone-like testosterone in man 
also regulates bone metabolism [80]. Zuo H, et al. in their 
prospective, open-label, randomized controlled clinical trial 
evaluated the effect of menopausal hormone therapy on bone 
mineral density in Chinese women belonging to 03 groups, group 
(A) receiving 0.625 mg conjugated equine estrogen (CEE)+100 mg 
micronized progesterone (MP) followed by group (B) receiving 0.3 
mg CEE daily+100 mg MP and group (C) receiving 0.625 mg CEE+10 
mg dihydrogesterone daily. The results summarized above indicates 
that there is a significant (P<0.01) increase, i.e. 2.31% and 1.95% in 
bone mineral density of group A and B. There is an elevation in bone 
mineral density of lumbar, femoral neck and ward triangle with both 
lower and standard doses of CEE with a reduced bone turnover [72].  
CONCLUSION 
On the basis of the evidence, it has been established that patient 
having thyroid disorder are at a greater risk of developing 
osteoporosis. A drop in the quality of bones has been observed in the 
person having any kind of thyroid disorder. Both hyper and 
hypothyroidism affect bone function in a very abysmal way and they 
are also the predictor of osteoporosis. From all the reported data, it’s 
clear that thyroid hormone affects the development of bone tissue, 
and we are trying to generate the specific data, while the molecular 
mechanism is still very complex. Our study demonstrated that 
thyroid disorder is a frequent medical problem and require medical 
attention. Thyroid hormone serves as necessary components for the 
normal functioning of bone tissue.  
In aggregate, our finding might help in refining the association 
between thyroid dysfunction and osteoporosis. Although it’s not too 
difficult to assess the effect of thyroid hormones on skeletal integrity 
(bone mineral density, bone mass, bone cell), as well as in 
osteoclasts and osteoblasts, which in turn, reinforces the importance 
of early diagnosis of thyroid disorders.  
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